secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prelude Therapeutics Inc (PRLD)
CIK:        0001678660
Form:       8-K
Filed at:   2025-03-10T23:59:59+00:00
Accession:  0000950170-25-035917
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prelude Therapeutics FY2024 net loss $127.2M; cash runway into Q2 2026
----------------------------------------------------------------------

- Net loss $127.2M ($1.68/share) vs $121.8M ($2.02/share) in FY2023; R&D expense rose to $118.0M.
- Cash, equivalents and marketable securities $133.6M at Dec 31, 2024; runway into Q2 2026.
- PRT3789 showed 5 confirmed partial responses in NSCLC, gastric, esophageal cancer; safety acceptable.
- PRT7732 oral SMARCA2 degrader Phase 1 enrollment ongoing; interim data expected H2 2025.
- Bryant Lim named permanent CFO; company to seek partner for PRT2527 CDK9 program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1678660/000095017025035917/0000950170-25-035917-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1678660/000095017025035917/prld-20250310.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-035917

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer